Phibro Animal Health (NASDAQ:PAHC) Updates FY 2025 Earnings Guidance

Phibro Animal Health (NASDAQ:PAHC) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 1.870-2.010 for the period, compared to the consensus earnings per share estimate of 1.710. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.

Phibro Animal Health Stock Up 0.9 %

Shares of NASDAQ:PAHC traded up $0.23 during midday trading on Friday, reaching $24.81. The company’s stock had a trading volume of 15,045 shares, compared to its average volume of 146,596. The company has a quick ratio of 1.69, a current ratio of 3.23 and a debt-to-equity ratio of 1.81. The firm has a market capitalization of $1.00 billion, a P/E ratio of 57.70, a PEG ratio of 0.56 and a beta of 0.52. Phibro Animal Health has a 12-month low of $10.03 and a 12-month high of $25.98. The firm has a 50 day moving average of $21.87 and a 200-day moving average of $21.60.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.40 by $0.14. Phibro Animal Health had a return on equity of 21.59% and a net margin of 1.67%. On average, research analysts anticipate that Phibro Animal Health will post 1.62 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 26th. Investors of record on Wednesday, March 5th will be issued a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 1.93%. The ex-dividend date is Wednesday, March 5th. Phibro Animal Health’s payout ratio is currently 111.63%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on PAHC. StockNews.com lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Thursday. Barclays increased their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a report on Tuesday, November 12th. Finally, Morgan Stanley upped their target price on Phibro Animal Health from $20.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 17th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $20.50.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.